# ![@Nuvectis Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1788895207481651200.png) @Nuvectis Nuvectis Pharma

Nuvectis Pharma posts on X about $nvct, release, announces, financial the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1788895207481651200/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1788895207481651200/c:line/m:interactions.svg)

- [--] Week [---] +230%
- [--] Month [---] +369%
- [--] Months [-----] -26%
- [--] Year [------] +170%

### Mentions: [--] [#](/creator/twitter::1788895207481651200/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1788895207481651200/c:line/m:posts_active.svg)

- [--] Month [--] +400%
- [--] Months [--] no change
- [--] Year [--] +55%

### Followers: [--] [#](/creator/twitter::1788895207481651200/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1788895207481651200/c:line/m:followers.svg)

- [--] Months [--] +28%
- [--] Year [--] +76%

### CreatorRank: undefined [#](/creator/twitter::1788895207481651200/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1788895207481651200/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [finance](/list/finance) 

**Social topic influence**
[$nvct](/topic/$nvct), [release](/topic/release), [announces](/topic/announces), [financial](/topic/financial), [business](/topic/business), [public](/topic/public), [common](/topic/common), [data](/topic/data), [virtual](/topic/virtual), [update](/topic/update)

**Top assets mentioned**
[Nuvectis Pharma, Inc.  (NVCT)](/topic/$nvct)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock $NVCT https://finance.yahoo.com/news/nuvectis-pharma-announces-pricing-13-140100888.html https://finance.yahoo.com/news/nuvectis-pharma-announces-pricing-13-140100888.html"  
[X Link](https://x.com/anyuser/status/1887168886564327575)  2025-02-05T15:58Z [--] followers, [---] engagements


"Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC $NVCT Read more: https://www.globenewswire.com/news-release/2025/03/04/3036465/0/en/Nuvectis-Pharma-Announces-a-New-Publication-of-a-Research-Study-Demonstrating-that-the-Combination-of-NXP900-and-EGFR-Inhibitors-Improves-the-Efficacy-of-the-EGFR-Inhibitors-in-Pre.html"  
[X Link](https://x.com/anyuser/status/1896932785576915177)  2025-03-04T14:36Z [--] followers, [----] engagements


"Please refer to the full press release which can be accessed using the following link: $NVCT https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html"  
[X Link](https://x.com/anyuser/status/1857034078454780060)  2024-11-14T12:13Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/07/08/3111700/0/en/Nuvectis-Pharma-Announces-Successful-Completion-of-a-Drug-Drug-Interaction-Study-in-Healthy-Volunteers-Supporting-NXP900-s-Potential-as-a-Combination-Partner-with-Leading-Therapies.html"  
[X Link](https://x.com/anyuser/status/1942556356239671759)  2025-07-08T12:08Z [--] followers, [---] engagements


"Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the [----] AACR Meeting $NVCT https://www.globenewswire.com/news-release/2025/04/29/3070800/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-Meeting.html https://www.globenewswire.com/news-release/2025/04/29/3070800/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-Meeting.html"  
[X Link](https://x.com/Nuvectis/status/1917345549734289783)  2025-04-29T22:29Z [--] followers, [----] engagements


"$NVCT Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference on May 20th [----] https://www.globenewswire.com/news-release/2025/05/16/3083407/0/en/Nuvectis-Pharma-to-Present-at-the-H-C-Wainwright-BioConnect-Investor-Conference.html https://www.globenewswire.com/news-release/2025/05/16/3083407/0/en/Nuvectis-Pharma-to-Present-at-the-H-C-Wainwright-BioConnect-Investor-Conference.html"  
[X Link](https://x.com/Nuvectis/status/1923742836135960748)  2025-05-17T14:10Z [--] followers, [----] engagements


"$NVCT Nuvectis Pharma Inc. Reports Second Quarter [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/08/05/3127240/0/en/Nuvectis-Pharma-Inc-Reports-Second-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/08/05/3127240/0/en/Nuvectis-Pharma-Inc-Reports-Second-Quarter-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/1952695546797302137)  2025-08-05T11:37Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Appoints Biotech Executive Juan Sanchez MD to the Board of Directors Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/09/25/3156222/0/en/Nuvectis-Pharma-Appoints-Biotech-Executive-Juan-Sanchez-MD-to-the-Board-of-Directors.html https://www.globenewswire.com/news-release/2025/09/25/3156222/0/en/Nuvectis-Pharma-Appoints-Biotech-Executive-Juan-Sanchez-MD-to-the-Board-of-Directors.html"  
[X Link](https://x.com/anyuser/status/1971184908446871688)  2025-09-25T12:07Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the [----] AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/10/16/3167841/0/en/Nuvectis-Pharma-Announces-Upcoming-Presentations-for-NXP900-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html"  
[X Link](https://x.com/anyuser/status/1978795045567209812)  2025-10-16T12:07Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the [----] AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/10/27/3174533/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html"  
[X Link](https://x.com/anyuser/status/1982781016839242238)  2025-10-27T12:06Z [--] followers, [---] engagements


"Big News We're excited to announce that Orphan Drug Designation was Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian Fallopian Tube and Primary Peritoneal Cancers 🧬 $NVCT Read more https://finance.yahoo.com/news/nuvectis-pharma-announces-orphan-drug-120000775.html https://finance.yahoo.com/news/nuvectis-pharma-announces-orphan-drug-120000775.html"  
[X Link](https://x.com/Nuvectis/status/1829138741514174891)  2024-08-29T12:47Z [--] followers, [----] engagements


"We recently announcned Upcoming Presentations for NXP900 at the [----] AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics $NVCT https://finance.yahoo.com/news/nuvectis-pharma-announces-upcoming-presentations-120000112.html https://finance.yahoo.com/news/nuvectis-pharma-announces-upcoming-presentations-120000112.html"  
[X Link](https://x.com/Nuvectis/status/1850925624161951854)  2024-10-28T15:40Z [--] followers, [---] engagements


"Today we reported our financial results for the third quarter of and provided an update on recent business progress. $NVCT Full announcement can be found here https://finance.yahoo.com/news/nuvectis-pharma-inc-reports-third-120000303.html https://finance.yahoo.com/news/nuvectis-pharma-inc-reports-third-120000303.html"  
[X Link](https://x.com/Nuvectis/status/1853781403684446294)  2024-11-05T12:48Z [--] followers, [---] engagements


"We are solidifying our plans for the next stage of development with both single agent & combination approaches to unlock the full therapeutic potential of NXP900 especially in NSCLC in combination with currently approved targeted therapies to overcome acquired resistance $NVCT"  
[X Link](https://x.com/Nuvectis/status/1853781409728540776)  2024-11-05T12:48Z [--] followers, [---] engagements


"We continue to be responsible and efficient with our financial resources and believe that our current cash position will allow us to meet important milestones for both clinical programs and provide working capital well into [----]. Keep reading : $NVCT http://finance.yahoo.com/news/nuvectis-pharma-inc-reports-third-120000303.html http://finance.yahoo.com/news/nuvectis-pharma-inc-reports-third-120000303.html"  
[X Link](https://x.com/Nuvectis/status/1853781412798681465)  2024-11-05T12:48Z [--] followers, [---] engagements


"Today we reported encouraging interim data from the Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer patients. The data support ongoing enrollment with promising results on safety and efficacy. $NVCT 🧵 https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html"  
[X Link](https://x.com/anyuser/status/1857034062151532911)  2024-11-14T12:13Z [--] followers, [----] engagements


"$NVCT CEO Ron Bentsur highlight the anti-tumor activity observed and the single agent activity observed in NXP800 alongside the companies confidence that with increased exposure NXP800 will potentially be demonstrate enhanced activity with acceptable tolerability"  
[X Link](https://x.com/anyuser/status/1857034074482741301)  2024-11-14T12:13Z [--] followers, [---] engagements


"Today we announced that we are going to Present at the [----] Ladenburg Virtual Oncology Innovators & Investors Symposium For more details $NVCT https://finance.yahoo.com/news/nuvectis-pharma-present-2024-ladenburg-130000478.html https://finance.yahoo.com/news/nuvectis-pharma-present-2024-ladenburg-130000478.html"  
[X Link](https://x.com/Nuvectis/status/1866644922469847531)  2024-12-11T00:43Z [--] followers, [---] engagements


"Today we Announced the Closing of a $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriters Over-Allotment Option $NVCT Read the full release: https://globenewswire.com/news-release/2025/02/07/3022784/0/en/Nuvectis-Pharma-Announces-Closing-of-15-5-Million-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriter-s-Over-Allotment-Option.html https://globenewswire.com/news-release/2025/02/07/3022784/0/en/Nuvectis-Pharma-Announces-Closing-of-15-5-Million-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriter-s-Over-Allotment-Option.html"  
[X Link](https://x.com/Nuvectis/status/1887859007831855182)  2025-02-07T13:40Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/07/31/3124897/0/en/Nuvectis-Pharma-Provides-Final-Clinical-Data-Update-from-the-NXP800-Phase-1b-Study-in-Ovarian-Cancer-and-Reports-Completion-of-the-NXP900-Phase-1a-Dose-Escalation-Study.html"  
[X Link](https://x.com/anyuser/status/1950886798143439319)  2025-07-31T11:50Z [--] followers, [----] engagements


"$NVCT Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/08/11/3131309/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Program-for-NXP900.html https://www.globenewswire.com/news-release/2025/08/11/3131309/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Program-for-NXP900.html"  
[X Link](https://x.com/anyuser/status/1955005499696468366)  2025-08-11T20:36Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Inc. Reports Third Quarter [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/11/04/3180214/0/en/Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/11/04/3180214/0/en/Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/1985687556835389564)  2025-11-04T12:36Z [--] followers, [----] engagements


"$NVCT CORRECTION: Nuvectis Pharma Inc. Reports Third Quarter [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/11/04/3180321/0/en/CORRECTION-Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/11/04/3180321/0/en/CORRECTION-Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/1985699133957538016)  2025-11-04T13:22Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors Including the Combination with Osimertinib in NSCLC Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/11/25/3194268/0/en/Nuvectis-Pharma-to-Host-a-Virtual-Key-Opinion-Leader-Meeting-to-Discuss-the-NXP900-Phase-1b-Program-in-Advanced-Solid-Tumors-Including-the-Combination-with-Osimertinib-in-NSCLC.html"  
[X Link](https://x.com/anyuser/status/1993347629724389393)  2025-11-25T15:54Z [--] followers, [----] engagements


"$NVCT Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html"  
[X Link](https://x.com/anyuser/status/2001262911788896682)  2025-12-17T12:07Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/09/04/3144379/0/en/Nuvectis-Pharma-to-Participate-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html https://www.globenewswire.com/news-release/2025/09/04/3144379/0/en/Nuvectis-Pharma-to-Participate-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html"  
[X Link](https://x.com/anyuser/status/1963566793278062664)  2025-09-04T11:36Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Inc. Reports [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2026/02/11/3236181/0/en/Nuvectis-Pharma-Inc-Reports-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2026/02/11/3236181/0/en/Nuvectis-Pharma-Inc-Reports-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/2021563781185171938)  2026-02-11T12:35Z [--] followers, [--] engagements


"$NVCT Nuvectis Pharma Inc. Reports [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2026/02/11/3236181/0/en/Nuvectis-Pharma-Inc-Reports-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2026/02/11/3236181/0/en/Nuvectis-Pharma-Inc-Reports-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/2021563781185171938)  2026-02-11T12:35Z [--] followers, [--] engagements


"$NVCT Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html"  
[X Link](https://x.com/anyuser/status/2001262911788896682)  2025-12-17T12:07Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors Including the Combination with Osimertinib in NSCLC Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/11/25/3194268/0/en/Nuvectis-Pharma-to-Host-a-Virtual-Key-Opinion-Leader-Meeting-to-Discuss-the-NXP900-Phase-1b-Program-in-Advanced-Solid-Tumors-Including-the-Combination-with-Osimertinib-in-NSCLC.html"  
[X Link](https://x.com/anyuser/status/1993347629724389393)  2025-11-25T15:54Z [--] followers, [----] engagements


"$NVCT CORRECTION: Nuvectis Pharma Inc. Reports Third Quarter [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/11/04/3180321/0/en/CORRECTION-Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/11/04/3180321/0/en/CORRECTION-Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/1985699133957538016)  2025-11-04T13:22Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Inc. Reports Third Quarter [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/11/04/3180214/0/en/Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/11/04/3180214/0/en/Nuvectis-Pharma-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/1985687556835389564)  2025-11-04T12:36Z [--] followers, [----] engagements


"$NVCT Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the [----] AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/10/27/3174533/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html"  
[X Link](https://x.com/anyuser/status/1982781016839242238)  2025-10-27T12:06Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the [----] AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/10/16/3167841/0/en/Nuvectis-Pharma-Announces-Upcoming-Presentations-for-NXP900-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html"  
[X Link](https://x.com/anyuser/status/1978795045567209812)  2025-10-16T12:07Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Appoints Biotech Executive Juan Sanchez MD to the Board of Directors Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/09/25/3156222/0/en/Nuvectis-Pharma-Appoints-Biotech-Executive-Juan-Sanchez-MD-to-the-Board-of-Directors.html https://www.globenewswire.com/news-release/2025/09/25/3156222/0/en/Nuvectis-Pharma-Appoints-Biotech-Executive-Juan-Sanchez-MD-to-the-Board-of-Directors.html"  
[X Link](https://x.com/anyuser/status/1971184908446871688)  2025-09-25T12:07Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/09/04/3144379/0/en/Nuvectis-Pharma-to-Participate-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html https://www.globenewswire.com/news-release/2025/09/04/3144379/0/en/Nuvectis-Pharma-to-Participate-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html"  
[X Link](https://x.com/anyuser/status/1963566793278062664)  2025-09-04T11:36Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/08/11/3131309/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Program-for-NXP900.html https://www.globenewswire.com/news-release/2025/08/11/3131309/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Program-for-NXP900.html"  
[X Link](https://x.com/anyuser/status/1955005499696468366)  2025-08-11T20:36Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Inc. Reports Second Quarter [----] Financial Results and Business Highlights Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/08/05/3127240/0/en/Nuvectis-Pharma-Inc-Reports-Second-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/08/05/3127240/0/en/Nuvectis-Pharma-Inc-Reports-Second-Quarter-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/anyuser/status/1952695546797302137)  2025-08-05T11:37Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/07/31/3124897/0/en/Nuvectis-Pharma-Provides-Final-Clinical-Data-Update-from-the-NXP800-Phase-1b-Study-in-Ovarian-Cancer-and-Reports-Completion-of-the-NXP900-Phase-1a-Dose-Escalation-Study.html"  
[X Link](https://x.com/anyuser/status/1950886798143439319)  2025-07-31T11:50Z [--] followers, [----] engagements


"$NVCT Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies Read the Full Press Release 👉 https://www.globenewswire.com/news-release/2025/07/08/3111700/0/en/Nuvectis-Pharma-Announces-Successful-Completion-of-a-Drug-Drug-Interaction-Study-in-Healthy-Volunteers-Supporting-NXP900-s-Potential-as-a-Combination-Partner-with-Leading-Therapies.html"  
[X Link](https://x.com/anyuser/status/1942556356239671759)  2025-07-08T12:08Z [--] followers, [---] engagements


"$NVCT Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference on May 20th [----] https://www.globenewswire.com/news-release/2025/05/16/3083407/0/en/Nuvectis-Pharma-to-Present-at-the-H-C-Wainwright-BioConnect-Investor-Conference.html https://www.globenewswire.com/news-release/2025/05/16/3083407/0/en/Nuvectis-Pharma-to-Present-at-the-H-C-Wainwright-BioConnect-Investor-Conference.html"  
[X Link](https://x.com/Nuvectis/status/1923742836135960748)  2025-05-17T14:10Z [--] followers, [----] engagements


"Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the [----] AACR Meeting $NVCT https://www.globenewswire.com/news-release/2025/04/29/3070800/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-Meeting.html https://www.globenewswire.com/news-release/2025/04/29/3070800/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-Meeting.html"  
[X Link](https://x.com/Nuvectis/status/1917345549734289783)  2025-04-29T22:29Z [--] followers, [----] engagements


"Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC $NVCT Read more: https://www.globenewswire.com/news-release/2025/03/04/3036465/0/en/Nuvectis-Pharma-Announces-a-New-Publication-of-a-Research-Study-Demonstrating-that-the-Combination-of-NXP900-and-EGFR-Inhibitors-Improves-the-Efficacy-of-the-EGFR-Inhibitors-in-Pre.html"  
[X Link](https://x.com/anyuser/status/1896932785576915177)  2025-03-04T14:36Z [--] followers, [----] engagements


"Today we Announced the Closing of a $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriters Over-Allotment Option $NVCT Read the full release: https://globenewswire.com/news-release/2025/02/07/3022784/0/en/Nuvectis-Pharma-Announces-Closing-of-15-5-Million-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriter-s-Over-Allotment-Option.html https://globenewswire.com/news-release/2025/02/07/3022784/0/en/Nuvectis-Pharma-Announces-Closing-of-15-5-Million-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriter-s-Over-Allotment-Option.html"  
[X Link](https://x.com/Nuvectis/status/1887859007831855182)  2025-02-07T13:40Z [--] followers, [---] engagements


"Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock $NVCT https://finance.yahoo.com/news/nuvectis-pharma-announces-pricing-13-140100888.html https://finance.yahoo.com/news/nuvectis-pharma-announces-pricing-13-140100888.html"  
[X Link](https://x.com/anyuser/status/1887168886564327575)  2025-02-05T15:58Z [--] followers, [---] engagements


"Today we announced that we are going to Present at the [----] Ladenburg Virtual Oncology Innovators & Investors Symposium For more details $NVCT https://finance.yahoo.com/news/nuvectis-pharma-present-2024-ladenburg-130000478.html https://finance.yahoo.com/news/nuvectis-pharma-present-2024-ladenburg-130000478.html"  
[X Link](https://x.com/Nuvectis/status/1866644922469847531)  2024-12-11T00:43Z [--] followers, [---] engagements


"Today we reported encouraging interim data from the Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer patients. The data support ongoing enrollment with promising results on safety and efficacy. $NVCT 🧵 https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html"  
[X Link](https://x.com/anyuser/status/1857034062151532911)  2024-11-14T12:13Z [--] followers, [----] engagements


"$NVCT CEO Ron Bentsur highlight the anti-tumor activity observed and the single agent activity observed in NXP800 alongside the companies confidence that with increased exposure NXP800 will potentially be demonstrate enhanced activity with acceptable tolerability"  
[X Link](https://x.com/anyuser/status/1857034074482741301)  2024-11-14T12:13Z [--] followers, [---] engagements


"Please refer to the full press release which can be accessed using the following link: $NVCT https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html https://finance.yahoo.com/news/nuvectis-pharma-reports-encouraging-nxp800-120000156.html"  
[X Link](https://x.com/anyuser/status/1857034078454780060)  2024-11-14T12:13Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing